52 matches.
- Media CoverageBradley Merrill Thompson Quoted in “Convergence: Experts Offer Advice on Leveraging AI in Regulatory”3 minute read
- Firm AnnouncementsEpstein Becker Green Earns Finalist Spots in New Jersey Law Journal's 2024 Legal Awards: Celebrating Excellence in Litigation and Mentorship4 minute read
- PublicationsFTC Releases Controversial Interim Staff Report on PBMs’ Purported Impact on Drug Prices3 minute read
- BlogsRecent Supreme Court Decisions and the DSCSA15 minute read
- The DEA Is Knocking at Your Door . . . Are You Prepared?
- BlogsFDA Guidance on DSCSA Small Dispenser Exemption and Exemptions and Waivers for Other Trading Partners13 minute read
- Media CoverageBradley Merrill Thompson Cited in “AI Regulation: Global Picture Balances Innovation and Insight”3 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Experts Advise Against Prescriptive FDA Policies for Regulating AI”3 minute read
- Media CoverageJames Boiani Quoted in “Jazz Pharma to Fight FDA in Court Over Rival Sleep Drug Approval”5 minute read
- Media CoverageTheodora McCormick Quoted in “‘Vague’ NY Law Looms for the Vitamin Shoppe, Other Supplement Retailers”3 minute read
- Media CoverageTeddy McCormick Quoted in “NPA to Seek Injunction Against NY Law Related to Weight Loss Supplements”4 minute read
- Media CoverageMaximilian Cadmus and William Gibson Featured in “New Partners Yearbook 2024”2 minute read
- Media CoverageJames Boiani Quoted in “Clinical Lab Consolidation Continues in 2023 While Key Policy Questions Go Unresolved”2 minute read
- Media CoverageJames Boiani Quoted in “FDA Braces for High Court, Final Rule Moves in Election Year”3 minute read
- Firm AnnouncementsEpstein Becker Green Announces 2024 Promotions6 minute read
- PublicationsChecking In on How SuperValu Has Altered FCA Litigation4 minute read
- PublicationsDietary Supplement Makers Face "Misbranding" Minefield, Need FDA Guidance7 minute read
- Post-Dobbs: One Year Later
- The Legal Battle Over Mifepristone
- Media CoverageBradley Merrill Thompson and the CDS Coalition Request FDA Rescind Final Decision Support Guidance2 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Why Congress Quietly Just Gave the FDA More Power”3 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Industry Group Petitions FDA to Withdraw CDS Guidance”5 minute read
- EventsSupplySide West 2022: State of Dietary Supplement Regulations and Litigation—2022 UpdateNovember 3, 20222 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Software to Predict Risk of Sepsis, Stroke Should Be Regulated as a Medical Device, Says FDA”4 minute read
- Media CoverageBradley Merrill Thompson Quoted in “FDA’s Tweak of Mobile Medical Apps Guidance Introduces Transparency Requirement”2 minute read
- Media CoverageBradley Merrill Thompson Quoted in “FDA Lays Out CDS Stance”1 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Legal Expert: FDA’s CDS Software Guidance Is a ‘Disaster’ for Industry”3 minute read
- Media CoverageBradley Merrill Thompson Quoted in “FDA Finalizes Guidance on How Clinical Decision Support Software Is Regulated”2 minute read
- Media CoverageBradley Merrill Thompson Featured in BioWorld: Discussion of FDA Guidance for CDS Software1 minute read
- Media CoverageBradley Merrill Thompson Quoted in “FDA Guidance Hikes Oversight of Clinical Decision Support Software”3 minute read
- Media CoverageBradley Merrill Thompson Quoted in “FDA Talks Takeaways from Software Precert Pilot”2 minute read
- Media CoverageEpstein Becker Green’s Unpacking Averages Report “Casts Doubt on Value of US FDA’s Breakthrough Devices Program”2 minute read
- EventsHatch-Waxman Litigation in the District of New Jersey: A Primer for the Jurist and the PractitionerMay 12, 20221 minute read
- Firm AnnouncementsEpstein Becker Green’s Theodora McCormick Recognized as a Trailblazing Change-Maker by the Executive Women of New Jersey4 minute read
- PublicationsPrescription Digital Therapeutics Don't Need a Physician3 minute read
- Media CoverageTheodora McCormick Quoted in “The Top Product Liability Cases of 2021”2 minute read
- Is the Dietary Supplement Regulatory Framework Working?
- EventsThe Year in Review: Food and Dietary Supplement Industry Trends, Key Court Decisions, and Litigation DevelopmentsSeptember 28, 20211 minute read
- Firm AnnouncementsEpstein Becker Green Launches Commercial Litigation Update Blog to Highlight Litigation Concerns for Businesses and Organizations3 minute read
- PublicationsAntitrust Law Compliance During Public Health Emergencies2 minute read
- Firm AnnouncementsCorporate Counsel Rank Epstein Becker Green as "Litigation Standout" in BTI Litigation Outlook 2020 Report2 minute read
- Media CoverageBradley Merrill Thompson Quoted in "Device Lawyer: FDA's Pre-Cert Update Seems Promotional, Lacks Answers"3 minute read
- Media CoverageJames Boiani Quoted in "What's Next for the Post-Gottlieb FDA"3 minute read
- Media CoverageStuart Gerson Quoted in "Drug, Device Lobbies Weigh In on Utah Device Liability Case"1 minute read
- EventsSeton Hall Law: U.S. Healthcare Compliance Certification Program - An Overview of Federal and Private Health Care Programs for Drug and Device Manufacturers1 minute read
- EventsFDLI: Introduction to US Medical Device Law and Regulation - Overview of Medical Device Law and Regulation Organizational Structures1 minute read
- Media CoverageStuart Gerson Quoted in "Pharma Charity's Suit Tests OIG's Kickback Oversight"2 minute read
- Media CoverageBradley Merrill Thompson Quoted in "Don't Wait for the Apple Watch to Dole Out Medical Advice Anytime Soon"2 minute read
- Media CoverageBradley Merrill Thompson Quoted in "Reject Off-Label Drug, Device Promotion Bills, Groups Tell Lawmakers"2 minute read
- Media CoverageBradley Merrill Thompson Quoted in "Senators Want to Fix FDA's Inspection Process for Device Companies"2 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Include Risk Tolerance Info in Device Approval Requests: FDA”1 minute read
- Media CoverageBradley Merrill Thompson Quoted in “Medical Software Group Presses FDA for Regulatory Clarity”2 minute read